Merck's new 'not Ivermectin' Covid-19 treatment, molnupiravir, costs $17.74 to produce - yet the company is charging the US government $712 for the treatment - a 40x markup, according to The Intercept, citing a report issued last week by the Harvard School of Public Health and King's College Hospital in London.
News of the oral 'wonder drug' sent shares of Merck higher last week, as the company says it can deliver 10MM doses by the end of the year.
Clearly, the pill could bring in massive profits to Merck and its partner on the drug, Ridgeback Biotherapeutics - which licensed the drug from Emory University in 2020 and then sold the worldwide rights to the drug to Merck for a sum which has not been disclosed.
Widely prescribed anti-parasitic Ivermectin has shown massive efficacy worldwide in the treatment of mild and moderate cases of Covid-19, plus as a prophylactic.
Ivermectin as a potential treatment for mild to moderate COVID-19 - A double blind randomized placebo-controlled trial.
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Wednesday, October 6, 2021
Merck Charging US 40 Times What It Costs To Make Govt-Financed COVID Pill
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment